Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rashid Khan

Internal Medicine Cincinnati, OH Medical Doctor

NPI 1972525046 CMS profile 44171

1380 Compton Rd, Cincinnati, OH 45231

Open in the dashboard

General payments

$9,111

583 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rashid Khan of Cincinnati, OH is reported in the CMS Open Payments database as having received $9,111 across 583 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,118 60
2024 General $847 46
2023 General $1,294 83
2022 General $1,741 110
2021 General $1,865 139
2020 General $1,209 84
2019 General $1,037 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rashid Khan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rashid Khan were reported at $1,118. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rashid Khan Internal Medicine median Middle half National median
2019 $1,037 $159 $48–$570 $163
2020 $1,209 $119 $33–$402 $114
2021 $1,865 $135 $37–$521 $132
2022 $1,741 $141 $42–$496 $149
2023 $1,294 $149 $45–$519 $160
2024 $847 $154 $47–$537 $164
2025 $1,118 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,181 61 payments
  2. AstraZeneca Pharmaceuticals LP $1,051 34 payments
  3. AbbVie, Inc. $891 89 payments
  4. Novo Nordisk Inc $725 52 payments
  5. GlaxoSmithKline, LLC. $633 53 payments
  6. Abbott Laboratories $471 17 payments
  7. Otsuka America Pharmaceutical, Inc. $406 26 payments
  8. Lilly USA, LLC $335 21 payments
  9. Pfizer Inc. $316 30 payments
  10. Amarin Pharma Inc. $289 17 payments
  11. Other $2,812 183 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,061 582 payments
  2. Long term medical supply or device loan $50 1 payment
Products named General payments · program years 2019–2025
  1. Repatha $887 49 payments
  2. BREZTRI $684 9 payments
  3. Otezla $591 37 payments
  4. TRELEGY ELLIPTA $546 46 payments
  5. FARXIGA $530 13 payments
  6. Ozempic $417 29 payments
  7. REXULTI $406 26 payments
  8. UBRELVY $401 36 payments
  9. AIMOVIG $384 17 payments
  10. VRAYLAR $351 38 payments
  11. Other $6,573 442 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 99 drugs

Part D claims

4,470

Median for Internal Medicine: 777

Drug cost

$380,038

Median for Internal Medicine: $73,373

Branded share of claims

20.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 31 $61,093
Januvia Sitagliptin Phosphate Brand 48 $48,072
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 54 $47,956
Eliquis Apixaban Brand 45 $44,926
Farxiga Dapagliflozin Propanediol Brand 35 $26,669
Xarelto Rivaroxaban Brand 18 $23,889
Ozempic Semaglutide Brand 18 $20,276
Vraylar Cariprazine Hcl Brand 13 $19,826
Repatha Sureclick Evolocumab Brand 11 $14,922
Mounjaro Tirzepatide Brand 12 $12,635

The 10 drugs with the highest cost, of 99 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$134,328

Medicare's payments for the services billed

Medicare patients

96

Average age 72

Services billed

1,939

40 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Chronic kidney disease 40%
Diabetes 36%
Depression 26%
Ischemic heart disease 19%
Heart failure 18%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $154
$154 — —
Leqembi
  • Eisai Inc. $69
  • Biogen, Inc. $66
$135 — —
Repatha
  • Amgen Inc. $95
$95 11 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $75
$75 35 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

583 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record